Axant

Axant25 mg

Baclofen

Novus Pharmaceuticals Ltd.

Product Code : 1674
MRP 8.00
10% Off
Best PriceTk
/
Out Of Stock
1
Section

Alternatives

See All
Product Image
7% Off

Lioresal25 mg

Baclofen

Novartis (Bangladesh) Ltd.

21.10
22.69
Out Of Stock
Product Image
10% Off

Beklo25 mg

Baclofen

Opsonin Pharma Ltd.

180.72
200.80
Add to cart
Product Image
10% Off

Flexibac25 mg

Baclofen

Beacon Pharmaceuticals Ltd.

18.05
20.06
Add to cart
Product Image
10% Off

Flexifen25 mg

Baclofen

Incepta Pharmaceuticals Ltd.

14.40
16.00
Add to cart
Product Image
10% Off

Reflexen25 mg

Baclofen

NIPRO JMI Pharma Ltd.

18.05
20.06
Add to cart
Section

Medicine overview

Indications of Axant 25 mg

Axant 25 mg is indicated in- spasticity resulting from multiple sclerosis flexor spasms and concomitant pain, clonus and muscular rigidity skeletal muscle spasm resulting from rheumatic disorders spinal cord injuries and other spinal cord diseases cerebrovascular accidents or neoplastic or degenerative brain disease

Theropeutic Class

Centrally acting Skeletal Muscle Relaxants

Pharmacology

Axant 25 mg is an effective muscle relaxant and antispastic agent with a spinal site of action. Its mode of action is not fully understood. Axant 25 mg inhibits both monosynaptic and polysynaptic reflexes at the spinal level by stimulating the GABAB-receptors, which inhibits the release of glutamate and aspartate. It may also act at intraspinal sites producing CNS depression. Neuromuscular transmission is not affected by Axant 25 mg. Axant 25 mg also exerts an antinoceptive effect but the clinical significance of this is unknown.

Dosage & Administration of Axant 25 mg

Axant 25 mg should be taken during meals with a little liquid. Axant 25 mg should be given in divided doses preferably 3 times daily for adults and 4 times daily for children. The lowest dose compatible with an optimal response is recommended. If benefits are not evident after a 6 to 8 week trial period, patients should be slowly withdrawn from the drug.Adults: Start therapy at low dosage and increase gradually until optimum effect is achieved (usually between 30-80mg daily). The following dosage titration schedule is suggested: 5 mg three times a day for 3 days 10 mg three times a day for 3 days 15 mg three times a day for 3 days 20 mg three times a day for 3 days Thereafter additional increases may be necessary, but the total daily dose should usually not exceed a maximum of 80 mg, although in hospitalized patients daily doses of 100-120 mg may occasionally be necessary.Children: Treatment should be started at a very low dose e.g. 0.3 mg/kg per day in divided doses. The dosage should be raised cautiously at 1-2 week intervals until it is sufficient for the child's individual needs. The usual dosage range for maintenance therapy is 0.75 to 2 mg/kg body weight per day. In children aged over 10 years a maximum daily dose of 2.5mg/kg bodyweight may be given.

Dosage of Axant 25 mg

Adult & children over 10 years: 5 mg 3 times daily, preferably with or after food, gradually increased; max. 100 mg daily.Children <10 years: Treatment is usually started with 2.5 mg (2.5 ml) given 4 times daily then raised according to requirement. Daily maintenance dose- 12 month-2 years: 10-20 mg (10-20 ml) 2 years-6 years: 20-30 mg (20-30 ml) 6 years-10 years: 30-60 mg (30-60 ml)

Interaction of Axant 25 mg

Increased sedation may occur if Axant 25 mg is taken with agents acting on the central nervous system, alcohol or synthetic opiates. The risk of respiratory depression is also increased. Combined treatment with Axant 25 mg and antihypertensives is likely to increase the fall in blood pressure; therefore the dosage of antihypertensive medication should be adjusted accordingly. The concomitant administration of Axant 25 mg and tricyclic antidepressants may potentiate the pharmacological effects of Axant 25 mg resulting in pronounced muscular hypotonia. In patients with Parkinsons disease receiving treatment with Axant 25 mg and levodopa and carbidopa, there have been several reports of mental confusion, hallucinations, headaches, nausea and agitation. The concurrent use of MAO inhibitors and Axant 25 mg may result in increased CNS depressant effects. Caution is advised and the dosage of one or both agents should be adjusted accordingly. Caution should be exercised when administering Axant 25 mg and magnesium sulphate or other neuromuscular blocking agents since a synergistic effect may theoretically occur.

Contraindications

Axant 25 mg is contraindicated in patients with hypersensitivity to any component of this product.

Side Effects of Axant 25 mg

The most common adverse reactions associated with Axant 25 mg are transient drowsiness, daytime sedation, dizziness, weakness and fatigue. Central Nervous System: Headache (<10%), insomnia (<10%), and rarely, euphoria, excitement, depression, confusion, hallucinations, paraesthesia, nightmares, muscle pain, tinnitus, slurred speech, co-ordination disorder, tremor, rigidity, dystonia, ataxia, blurred vision, nystagmus, strabismus, miosis, mydriasis, diplopia, dysarthria, epileptic seizures, respiratory depression. Cardiovascular: Hypotension (<10%), rare instances of dyspnoea, palpitation, chest pain, syncope. Gastrointestinal: Nausea (approximately 10%), constipation (<10%) and rarely, dry mouth, anorexia, taste disorder, abdominal pain, vomiting, diarrhoea and positive test for occult blood in stool. Genitourinary: Urinary frequency (<10%) and rarely, enuresis, urinary retention, dysuria, impotence, inability to ejaculate, nocturia, haematuria. Other: Instances of rash, pruritus, ankle oedema, excessive perspiration, weight gain, nasal congestion, visual disturbances, hepatic function disorders and paradoxical increase in spasticity. Muscular hypotonia of a degree sufficient to make walking or movement difficult may occur but is usually relieved by readjusting the dosage. For this purpose, the daytime dosage may be reduced and the evening dosage increased.

Pregnancy & Lactation

Pregnancy category B3. Safe use of Axant 25 mg during pregnancy has not been established. Axant 25 mg crosses the placental barrier. Axant 25 mg should only be administered to pregnant women when in the judgement of the physician concludes that the potential benefits outweigh the possible hazards. Axant 25 mg is excreted in breast milk however evidence to date suggests that the quantities are so small that no undesirable effects on the infant would be expected.

Precautions & Warnings

Lower doses (approximately 5 mg per day) should be used for patients with impaired renal function or those undergoing chronic haemodialysis. Patients suffering not only from spasticity but also from psychotic disorders, schizophrenia, depressive or manic disorders or confusional states should be treated cautiously and closely monitored as exacerbations of these disorders may occur. In patients with epilepsy and muscle spasticity, Axant 25 mg may be used under appropriate supervision and provided that adequate anticonvulsive therapy is continued. Lowering of the convulsion threshold may occur and seizures have been reported after the cessation of Axant 25 mg therapy or with overdose. Axant 25 mg should be used with caution in patients with or with a history of peptic ulcers, cerebrovascular diseases, or hepatic, renal or respiratory failure. Careful monitoring of respiratory and cardiovascular function is essential especially in patients with cardiopulmonary disease and respiratory muscle weakness. During treatment with Axant 25 mg, neurogenic disturbances affecting emptying of the bladder may improve. However in patients with preexisting sphincter hypertonia, acute retention of urine may occur. Axant 25 mg should be used with caution in these circumstances. Axant 25 mg has not significantly benefited patients with stroke. These patients have also shown poor tolerance to the medicine. Appropriate laboratory tests should be performed periodically in patients with hepatic diseases or diabetes mellitus to ensure that no medicine induced changes in these underlying diseases have occurred.

Overdose Effects of Axant 25 mg

Gastric lavage is important in case of severe overdose.

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Drug Classes

Centrally acting Skeletal Muscle Relaxants

Mode Of Action

Axant 25 mg inhibits both monosynaptic and polysynaptic reflexes at the spinal level by stimulating the GABAB receptors, which inhibits the release of glutamate and aspartate. It may also act at intraspinal sites producing CNS depression. Axant 25 mg also exerts an antinociceptive effect.

Pregnancy

Pregnancy category B3. Safe use of Axant 25 mg during pregnancy has not been established. Axant 25 mg crosses the placental barrier. Axant 25 mg should only be administered to pregnant women when in the judgement of the physician concludes that the potential benefits outweigh the possible hazards. Axant 25 mg is excreted in breast milk however evidence to date suggests that the quantities are so small that no undesirable effects on the infant would be expected.
Disclaimer

The information provided is accurate to our best practices, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy. The absence of specific information about a drug should not be seen as an endorsement. We are not responsible for any consequences resulting from this information, so consult a healthcare professional for any concerns or questions.